Composite Cutaneous Lymphoma (Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorder) in a Patient with Rheumatoid Arthritis Treated with Methotrexate: Staging and Evaluation of Response to Therapy with ¹⁸F-FDG PET/CT
10.1007/s13139-016-0463-4
- Author:
William MAKIS
1
;
Anthony CIARALLO
;
Beatrice WANG
;
Milene GONZALEZ-VERDECIA
;
Stephan PROBST
Author Information
1. Department of Diagnostic Imaging, CCI, Diagnostic Imaging, 11560 University Ave NW, Edmonton, Alberta T6G 1Z2, Canada. makisw79@yahoo.com
- Publication Type:Case Report
- Keywords:
Composite lymphoma;
Cutaneous lymphoma;
Iatrogenic immunodeficiency-associated lymphoproliferative disorder;
Methotrexate;
PET/CT;
Rheumatoid arthritis
- MeSH:
Arthritis, Rheumatoid;
Composite Lymphoma;
Drug Therapy;
Electrons;
Female;
Humans;
Lymphoma;
Lymphoproliferative Disorders;
Methotrexate;
Positron-Emission Tomography and Computed Tomography;
Prednisone;
Skin
- From:Nuclear Medicine and Molecular Imaging
2017;51(3):261-265
- CountryRepublic of Korea
- Language:English
-
Abstract:
A 67 year old woman with a 10 year history of rheumatoid arthritis (RA) treated with methotrexate and prednisone, presented with a 2 year history of worsening multiple cutaneous plaques of variable appearance. Two distinct skin lesions were biopsied to reveal a composite cutaneous lymphoma, possibly caused by long term methotrexate therapy. An [18F] fluoro-2-deoxy-D-glucose (¹⁸F-FDG) positron emission tomography/computed tomography (PET/CT) was performed to stage the malignancy, and was later repeated to evaluate response to chemotherapy, which guided subsequent management. We present the PET/CT imaging findings of this very rare iatrogenic (methotrexate induced) immunodeficiency-associated lymphoproliferative disorder.
